Geron Corporation (GERN) News Headlines

▮ More

Date

Headline

5/9/2022 4:14:12 PM Geron Q1 Loss/share $0.09, Same As Last Year

5/9/2022 4:10:15 PM Geron Corporation Q1 Loss beats estimates

5/9/2022 3:30:24 PM Geron Q1 22 Earnings Conference Call At 4:30 PM ET

3/10/2022 4:12:37 PM Geron Corporation Q4 Loss increases, misses estimates

3/10/2022 4:11:04 PM Geron Corp. Q4 Loss/share $0.10 Vs. Loss $0.07 Year Ago

1/10/2022 6:00:17 AM Geron To Present At The H.C. Wainwright BioConnect Conference; Webcast At 7:00 AM ET

12/2/2021 7:33:26 AM Geron Appoints Edward Koval As EVP And Chief Business Officer

11/9/2021 6:50:00 PM Geron Corporation Q3 Earnings Summary

10/18/2021 7:36:20 AM Geron Completes Patient Enrollment In IMerge Phase 3 Trial In Lower Risk Myelodysplastic Syndromes

10/12/2021 5:47:30 AM Pre-market Movers: OCGN, QTRX, PETV, SLI, WWR…

9/30/2021 2:22:07 PM Geron To Present At Cantor Virtual Global Healthcare Conference; Webcast At 3:20 PM ET

9/14/2021 1:00:09 PM Geron To Present At R.W. Baird 2021 Virtual Global Healthcare Conference; Webcast At 2:00 PM ET

9/13/2021 6:00:18 AM Geron Corp. To Present At H.C. Wainwright Global Virtual Investment Conference; Webcast At 7:00 AM

8/16/2021 5:16:50 PM Geron Corporation Q2 Earnings Summary

8/16/2021 3:00:39 PM Geron Q2 21 Earnings Conference Call At 4:30 PM ET

5/12/2021 11:05:31 AM Geron Announces Two Presentations At Upcoming European Hematology Association Annual Congress

5/10/2021 4:27:25 PM EARNINGS SUMMARY: Details of Geron Corporation Q1 Earnings Report

5/10/2021 4:10:26 PM Geron Q1 Loss/Shr $0.09 Vs Loss $0.08 Last Year

4/13/2021 7:45:56 AM Geron Doses First Patient In IMpactMF Phase 3 Trial In Refractory Myelofibrosis - Quick Facts

4/13/2021 7:34:51 AM Geron Says First Patient Has Been Dosed In IMpactMF Phase 3 Clinical Trial In Refractory Myelofibrosis